This article has been updated to include information from Myriad's 10-Q filing and stock pricing information.

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its first quarter revenues in fiscal 2017 fell 3 percent, thanks in part to an 11 percent drop in hereditary cancer testing revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.